Bank of Jackson Hole Trust Takes Position in Zoetis Inc. (NYSE:ZTS)

Bank of Jackson Hole Trust purchased a new stake in Zoetis Inc. (NYSE:ZTS) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 3,932 shares of the company’s stock, valued at approximately $641,000.

A number of other institutional investors and hedge funds also recently modified their holdings of ZTS. Callahan Advisors LLC raised its holdings in Zoetis by 90.4% during the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after buying an additional 6,221 shares during the period. Kentucky Retirement Systems Insurance Trust Fund raised its holdings in Zoetis by 32.0% during the 4th quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 17,707 shares of the company’s stock worth $2,885,000 after buying an additional 4,293 shares during the period. BKM Wealth Management LLC raised its holdings in Zoetis by 7.5% during the 4th quarter. BKM Wealth Management LLC now owns 8,393 shares of the company’s stock worth $1,367,000 after buying an additional 584 shares during the period. Kestra Investment Management LLC raised its holdings in Zoetis by 106.9% during the 4th quarter. Kestra Investment Management LLC now owns 6,057 shares of the company’s stock worth $987,000 after buying an additional 3,129 shares during the period. Finally, Venturi Wealth Management LLC raised its holdings in Zoetis by 2.1% during the 4th quarter. Venturi Wealth Management LLC now owns 11,964 shares of the company’s stock worth $1,949,000 after buying an additional 250 shares during the period. 92.80% of the stock is owned by institutional investors.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is owned by insiders.

Zoetis Stock Down 0.7 %

ZTS opened at $156.43 on Wednesday. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The company has a market capitalization of $70.05 billion, a P/E ratio of 28.60, a P/E/G ratio of 2.71 and a beta of 0.90. The stock has a fifty day moving average of $167.70 and a 200-day moving average of $178.44.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, equities analysts expect that Zoetis Inc. will post 6.06 EPS for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.28%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Stifel Nicolaus decreased their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Piper Sandler decreased their price target on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. UBS Group initiated coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price for the company. Finally, Leerink Partners initiated coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price for the company. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Zoetis has a consensus rating of “Buy” and a consensus target price of $214.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.